Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Its hard to buy shares as the spead is still very large. I have over 100K but would like to get more.
That will be a very nice payday if things come together as expected.
holding 150K here
So thin between here and a dollar. If only they would get this thing going!
The spread is shrinking. I still wanna see some ask hittage.
Lets see if the bid can hold as it looks like someone is selling some at .0052
I see the possibility of a 510,000% one day gain here! That could be a record.
Bid 0.0001
Ask 0.51
lol
Looks like you can't buy or sell this right now. I have tried to do both for 3 days now.
Hmmm. Thanks for trying anyway. Whoever was on the ask at .40 appears to have moved up to .50. Lets hope we have news to go with that .50 ask.
niente!
filed at .004
but in my account filed at .40
Stück/Nominal Kurs Abrechnung
50,00 0,40 USD 20.11.2009 21:43:05
would be a 10.000 % bagger!!!
and we are on radar over all boards!
I just called TDA. The broker confirmed .004 x .40. I'd hit the ask myself, but I'm at work. Wait 'til a couple minutes before the close so I can hold a pile of cash over the weekend.:)
Oh yes. I'd love to see that .40.
think .40 is a mistake!
should i slap that ask!!???
way undervalued here
imho
Quick, someone hit the .40. This will be worth way more than .40 once they get rolling with their generic pipeline.
just waiting on news here for now hoping the insiders will buy more of the float
so they also will be interested for a higher pps as now!?
sounds like very defensiv from earl.....any more guesses lifegear......?
so many of them are stockholders too
email response from earl sullivan
Mr. XXXXX,
Thank you for contacting the company regarding your investment. At this time, the company is in a non-reporting status with the SEC. We do not anticipate that this status will change in the near future but will inform all shareholders if it does. Our focus is to reduce the cost structure of the company, focus on our Israeli subsidiary and to continue to focus on developing niche pharmaceutical products.
At the current time, we do not have another update to provide shareholders other than we continue to work on a daily basis to improve the position of the company. In these economic times it will be challenging but as many of the remaining staff are stockholders we are interested in doing our best.
We will add your name to our shareholder list with your current email so that future announcements from the company will come to you directly.
Best regards,
Earl
I'd like to pick up a few but concerned of about the legality of my doing so. I have ties to this company but I'm not sure if that makes me an "insider".
hey toxic,
you got a starter position?
FineTech pharmaceutical has an integrated team of 25 highly skilled and educated scientists led by Dr. Arie Gutman. This group has contributed to winning 75% "Paragraph IV" challenges, resulting in profits of more than $80 million for its clients. Additionally, it has completed development work for several of the world's leading pharmaceutical companies. finetech will continue its efforts in research and development, while maintaining a focus on the manufacture of active pharmaceutical ingredients (APIs) for RxElite and other preferred clients.
"With the new acquisition of finetech, our strategy to produce difficult product formulas has been extensively expanded to include complex APIs," commented Earl E. Sullivan, the COO of RxElite. "Dr. Gutman and his team are a world class addition to our capabilities and expanding markets."
"FineTech holds the patents on difficult to produce APIs, therefore generating significant non-US licensing opportunities, including annual royalty opportunities," said RxElite's SVP Business Development, Rick Schindewolf, "The acquisition of finetech has expanded RxElite's drug pipeline substantially, thus filling a critical need for our strategic partners in Asia, Europe, and Australia for several of our new key products both in APIs and finished dosage formats."
The worldwide market for the finished dosage pharmaceuticals represented by finetech's APIs is in excess of $4.5
'/>"/>
++++++FineTech achieved revenues of approximately $6 million in and 2007+++++
SOURCE RxElite, Inc.
Copyright©2008 PR Newswire.
All rights reserved
0
yup! and adding here........
yes that's why I'm still holding all my shares
they sold the subsidiary RxElite Holdings to that company Piramal
Piramal Healthcare
Name of acquired company Year of acquisition
Nicholas Labs 1988
Roche Products Limited 1993
Boehringer Mannheim 1996
Hoechst Research Centre 1998
Rhone Poulenc India Ltd. 2000
ICI Pharma 2002
Global Bulk Drugs 2003
Sarabhai Piramal 2003
Rhodia UK 2005
Avecia Pharmaceuticals 2005
Pfizer Morpeth Site 2006
Khandelwal Laboratories 2008
HLPL-Bangalore 2008
Minrad International Inc 2009
RxElite, Inc 2009
Today, we have JVs and alliances with some of the finest global names in the pharmaceutical and healthcare industry. In-licensing of brands enable us to bring the best innovation to our customers. Our current in-licensing agreement include the following:
Biogen
Chiesi
PFDC
GenzymeC
Gilead
http://piramalhealthcare.com/About-Us/Partnerships.aspx
look like a huge healthcare company.....WE ARE IN GOOD HANDS!???
would be nice to see a ask .002-.004 again to load up more shares!
have a good feeling here LG!
done today!
I hope sooner
BM`s up! a few more eyes over the last 2 days
lifegear,
whats your guesses here!?? could it be a winner sooner ore later??
Thx lifegear!!
nice to see a response from landela! NICE!!
no guess what it means! wondering why no change in name! saw this on pinksheets a few days ago.
will buy more next weeks!
are they saying the pps will rise soon?..."We would not be able at this time to comment on the stock price."
Email response from company...
Thank you for contacting the company regarding your investment in RxElite, Inc. The current name of the company is Landela Pharmaceutical but that is only a "doing business as" name for RxElite, Inc. In January 2009, RxElite sold RxElite Holdings, Inc (a wholly owned subsidiary) to Piramal Healthcare in India. To avoid market confusion we filed the dba certificate and changed the working name of RxElite, Inc. to Landela. It would require a shareholder vote and approval to change the name of the company in its entirety to Landela and at this time we are not anticipating asking for such a change. The stock symbol will remain RXEI and is traded on the pink sheets under RXEI.PK.
I am unaware that our website (www.landelapharma.com) mentions anything about future approvals of ANDAs. If it does, please point me to the specific page so that we can make appropriate corrections if necessary. We do have three approved ANDAs which are all currently not actively marketed. In the future this may change but we would need to find the appropriate outlet.
Our management team has focused on cutting expenses and refocusing the company. Our goal is to always protect shareholder value and we work diligently day to day to move the company forward. We would not be able at this time to comment on the stock price.
Best regards,
Earl E. Sullivan
Chief Executive Officer
Landela Pharmaceutical
776 East Riverside Drive
Suite 150
Eagle, Idaho 83616
will also email the company
thx lifegaer
no response, meanwhile I noticed the chart in ibox is heading towards a golden cross
no problem sir!
thanks for reminding me lol
lifegear,
you have emailed landela?
nasty whacker for a few bucks
I'll try email them and you're right, there should have been a name change by now even a stock symbol change.
email from february
"......Please note that it will take us 90-120 days to change the name with the SEC so for contracts we should use RxElite, Inc. dba Landela Pharmaceutical for this interim period...."
hey lifegear,
thought we see a name change based on shareholder update!
is it possible to contact landela pharm.!?
earl.sullivan@landelapharma.com
Followers
|
10
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
220
|
Created
|
10/21/08
|
Type
|
Free
|
Moderators |
About RxElite, Inc. dba Landela Pharmaceutical
RxElite, Inc. dba Landela Pharmaceutical is a specialty pharmaceutical company that develops and markets generic prescription drug products in specialty generic markets. The Company also operates an Israeli subsidiary that manufactures and markets complex active pharmaceutical ingredients and provides research and development services to pharmaceutical companies throughout the world.
http://www.landelapharma.com/releases/57-rxelite-inc-shareholder-update
SUBSIDIARY: FINETECH PHARMACEUTICAL
http://www.finetechlabs.com/index.php?option=com_content&task=view&id=20&Itemid=29
RxElite, Inc. Shareholder Update |
Thursday, 12 February 2009 09:50 |
Meridian, Idaho, February 12, 2009: RxElite, Inc. [RXEI.PK] announced today that it has determined to suspend reporting currently with the SEC. On February 3, 2009, RxElite filed Form 15, Certificate and Notice of Termination of Registration under Section 12(g) of the Securities Exchange Act of 1934, and no longer will be required to file mandatory reports with the SEC. According to Earl Sullivan, Chairman and CEO, “We made this decision in consultation with our senior lenders after which our board authorized suspension of reporting as a measure designed to reduce overhead and compliance costs following our recent sale of RxElite Holdings Inc., our wholly owned U.S. subsidiary, to Piramal Healthcare Limited (India).”
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |